StreetInsider.com News Articles

Ravi Chandran Krishnadas joins RWS as Senior Vice President & Country Lead, India

Mon, 01 Jun 2026 04:00:00 -0400

New country leadership reinforces RWS's commitment to India as a strategic hub for global AI innovation and client delivery

MAIDENHEAD, England, June 1, 2026 /PRNewswire/ -- RWS (AIM: RWS.L), a global AI solutions company, today announces that Ravi Chandran Krishnadas has joined as Senior Vice President & Country Lead, India, effective 1 June 2026. The appointment marks an important step in RWS's strategy to strengthen India as a major operations and innovation hub as demand for enterprise AI solutions continues to grow worldwide.

In his new

Ravi Chandran Krishnadas joins RWS as Senior Vice President & Country Lead, India

Mon, 01 Jun 2026 04:00:00 -0400

New country leadership reinforces RWS's commitment to India as a strategic hub for global AI innovation and client delivery

In his new

Ravi Chandran Krishnadas joins RWS as Senior Vice President & Country Lead, India

Mon, 01 Jun 2026 04:00:00 -0400

New country leadership reinforces RWS's commitment to India as a strategic hub for global AI innovation and client delivery

In his new

Ravi Chandran Krishnadas joins RWS as Senior Vice President & Country Lead, India

Mon, 01 Jun 2026 04:00:00 -0400

New country leadership reinforces RWS's commitment to India as a strategic hub for global AI innovation and client delivery

In his new

Ravi Chandran Krishnadas joins RWS as Senior Vice President & Country Lead, India

Mon, 01 Jun 2026 04:00:00 -0400

New country leadership reinforces RWS's commitment to India as a strategic hub for global AI innovation and client delivery

In his new

Ravi Chandran Krishnadas joins RWS as Senior Vice President & Country Lead, India

Mon, 01 Jun 2026 04:00:00 -0400

New country leadership reinforces RWS's commitment to India as a strategic hub for global AI innovation and client delivery

In his new

Form SCHEDULE 13G AIM ImmunoTech Inc. Filed by: INTRACOASTAL CAPITAL, LLC

Wed, 27 May 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260527/26559105.html

Form SCHEDULE 13G AIM ImmunoTech Inc. Filed by: INTRACOASTAL CAPITAL, LLC

Wed, 27 May 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260527/26559105.html

Form 8-K AIM ImmunoTech Inc. For: May 20

Thu, 21 May 2026 11:31:00 -0400

si-local-file:///var/storage/secattach/20260521/26533352.html

Form 8-K AIM ImmunoTech Inc. For: May 20

Thu, 21 May 2026 11:31:00 -0400

si-local-file:///var/storage/secattach/20260521/26533352.html

Form 424B5 AIM ImmunoTech Inc.

Thu, 21 May 2026 11:30:00 -0400

si-local-file:///var/storage/secattach/20260521/26533347.html

Form 424B5 AIM ImmunoTech Inc.

Thu, 21 May 2026 11:30:00 -0400

si-local-file:///var/storage/secattach/20260521/26533347.html

AIM ImmunoTech raises $2.4 million through stock and warrant offering

Wed, 20 May 2026 15:02:32 -0400

AIM ImmunoTech Inc. (NYSE American: AIM) announced it has entered into agreements for a $2.4 million financing consisting of a registered direct offering and concurrent private placement. The company will sell 7,519,351 shares of common stock at $0.325 per share through the registered offering.

In the concurrent private placement, AIM ImmunoTech will issue Series I warrants to purchase up to 15,038,702 shares of common stock. The warrants carry an exercise price of $0.325 per share, require stockholder approval to exercise, and expire five years from the initial exercise date.

Ladenburg Thalmann & Co. Inc. serves as the exclusive placement agent for the

AIM ImmunoTech raises $2.4 million through stock and warrant offering

Wed, 20 May 2026 15:02:32 -0400

Ladenburg Thalmann & Co. Inc. serves as the exclusive placement agent for the

AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement

Wed, 20 May 2026 15:02:00 -0400

OCALA, Fla., May 20, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”, today announced that it has entered into definitive agreements for a registered direct offering priced at-the-market under NYSE Rules of an aggregate of 7,519,351 shares of common stock, par value $0.001 per share (the “Common Stock”) (or common stock equivalents in lieu thereof) at a purchase price of $0.325 per share. The gross proceeds to the Company from the offering are expected to be approximately $2.4 million, before deducting placement agent commissions and other offering expenses. In addition, in a

AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement

Wed, 20 May 2026 15:02:00 -0400

AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement

Wed, 20 May 2026 15:02:00 -0400

AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement

Wed, 20 May 2026 15:02:00 -0400

AIM ImmunoTech (AIM) halted, news pending

Wed, 20 May 2026 14:58:17 -0400

AIM ImmunoTech (AIM) halted, news pending

Wed, 20 May 2026 14:58:17 -0400

AIM ImmunoTech (AIM) halted, news pending

Form 424B5 AIM ImmunoTech Inc.

Tue, 19 May 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260519/26522674.html

Form 424B5 AIM ImmunoTech Inc.

Tue, 19 May 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260519/26522674.html

AIM ImmunoTech extends debt maturity to 2027, reports equity increase

Tue, 19 May 2026 08:06:28 -0400

AIM ImmunoTech Inc. (NYSE American: AIM) announced it extended the maturity date of a promissory note with Streeterville Capital LLC to June 30, 2027, and reported an increase in stockholder equity to approximately $2.1 million as of March 31, 2026.

The company reported stockholder equity increased by approximately $11.9 million from a stockholder deficit of approximately $9.8 million as of December 31, 2025. AIM stated it has raised additional equity-generating funds through various transactions since March 31, 2026.

Under the amendment terms, the outstanding balance of the promissory note originally issued on February 16, 2024, is approximately $1.68 million following the extension

Form 8-K AIM ImmunoTech Inc. For: May 18

Tue, 19 May 2026 08:03:00 -0400

si-local-file:///var/storage/secattach/20260519/26517668.html

Form 8-K AIM ImmunoTech Inc. For: May 18

Tue, 19 May 2026 08:03:00 -0400

si-local-file:///var/storage/secattach/20260519/26517668.html